Covered recipient · General Payments record
DAVID L SLOTNICK
Allopathic & Osteopathic Physicians Internal Medicine
General Payments · PY2019–2024
$697.82
- Reported across 29 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $233.65 | 10 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $37.49 | 2 |
| PFIZER INC. | $37.28 | 1 |
| Nevro Corp. | $27.82 | 1 |
| Astellas Pharma US Inc | $26.68 | 1 |
| BOSTON SCIENTIFIC CORPORATION | $26.67 | 1 |
| GlaxoSmithKline, LLC. | $23.17 | 1 |
| Acerta Pharma LLC | $18.77 | 1 |
| Esperion Therapeutics, Inc. | $18.04 | 1 |
| ABBVIE INC. | $17.73 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (10)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $17.73 | 07/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106119760 | CMS |
| Astellas Pharma US Inc | $26.68 | 05/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139350309 | CMS |
| AstraZeneca Pharmaceuticals LP | $18.77 | 12/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104396213 | CMS |
| Boston Scientific Corporation | $26.67 | 01/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1092432335 | CMS |
| Esperion Therapeutics, Inc. | $18.04 | 05/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1129455932 | CMS |
| GlaxoSmithKline, LLC. | $23.17 | 07/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115722656 | CMS |
| Nevro Corp. | $27.82 | 04/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1130769262 | CMS |
| Novo Nordisk Inc | $17.32 | 08/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097568640 | CMS |
| Novo Nordisk Inc | $20.17 | 10/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097707977 | CMS |
| PFIZER INC. | $37.28 | 02/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131052431 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2019, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.